Gilead Sciences: Pseudomonas Infections trials
The registry lists 11 Pseudomonas Infections studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 2 2Phase 3 6No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower AirwaysCompletedNCT01404234Phase 3Results posted
- Aztreonam Lysine for Pseudomonas Infection Eradication StudyCompletedNCT01375049Phase 2Results posted
- Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas AeruginosaCompletedNCT00757237Phase 3Results posted
- Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. AeruginosaCompletedNCT00712166Phase 3Results posted
- Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)CompletedNCT00128492Phase 3Results posted
- International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. AeruginosaCompletedNCT00112359Phase 3Results posted
- Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. AeruginosaCompletedNCT00104520Phase 3Results posted
- Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis PatientsCompletedNCT01375036
- Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa InfectionCompletedNCT01055847Phase 2
- Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic FibrosisApproved for marketingNCT00989807
- Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway InfectionApproved for marketingNCT00499720